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Abstract: Enteropathogenic (EPEC) and Enterohemorrhagic (EHEC) Escherichia coli are considered emerg-
ing zoonotic pathogens of worldwide distribution. The pathogenicity of the bacteria is conferred by
multiple virulence determinants, including the locus of enterocyte effacement (LEE) pathogenicity
island, which encodes a type III secretion system (T3SS) and effector proteins, including the multi-
functional secreted effector protein (EspF). EspF sequences differ between EPEC and EHEC serotypes
in terms of the number and residues of SH3-binding polyproline-rich repeats and N-terminal lo-
calization sequence. The aim of this study was to discover additional cellular interactions of EspF
that may play important roles in E. coli colonization using the Yeast two-hybrid screening system
(Y2H). Y2H screening identified the anaphase-promoting complex inhibitor Mitotic Arrest-Deficient
2 Like 2 (MAD2L2) as a host protein that interacts with EspF. Using LUMIER assays, MAD2L2 was
shown to interact with EspF variants from EHEC O157:H7 and O26:H11 as well as EPEC O127:H6.
MAD2L2 is targeted by the non-homologous Shigella effector protein invasion plasmid antigen B
(IpaB) to halt the cell cycle and limit epithelial cell turnover. Therefore, we postulate that interactions
between EspF and MAD2L2 serve a similar function in promoting EPEC and EHEC colonization,
since cellular turnover is a key method for bacteria removal from the epithelium. Future work should
investigate the biological importance of this interaction that could promote the colonization of EPEC
and EHEC E. coli in the host.
Keywords: MAD2L2; interaction; effector proteins; EspF; Escherichia coli; pathogenesis
1. Introduction
Enteropathogenic and Enterohemorrhagic Escherichia coli (EPEC and EHEC, respectively)
constitute a significant major risk to human health worldwide [1]. In accordance with their
public concern, EPEC are a subgroup of medically important diarrhoeagenic E. coli that
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can cause severe infantile diarrheal diseases in the developing world, arising mainly from
human-to-human infection [2,3]. Furthermore, EPEC cause a serious intestinal disease
in many animal species, including cattle [4–6]. On the other hand, EHEC are a class of
Shiga-toxigenic E. coli (STEC) that are considered as a cause of potentially fatal foodborne
infections, arising from animal-to-human infection, where cattle are considered the main
reservoir host [7–9]. These emerging zoonotic pathogens are primarily found in indus-
trialized countries and cause sporadic outbreaks of severe disease in humans, including
hemorrhagic colitis (HC) and hemolytic uremic syndrome (HUS) [10]. Among others,
E. coli O157:H7 is the predominant EHEC serotype associated with human disease in
industrialized countries and recently is considered a leading cause of HUS [5,11–13]. Both
EPEC and EHEC are defined by their capacity to adhere to host gastrointestinal cells and
inject effector proteins, including their own anchoring and signaling receptor, via a type III
secretion system (T3SS) that is encoded by the chromosomal locus of enterocyte effacement
(LEE), a pathogenicity island that encodes many virulence factors important for EPEC
and EHEC pathogenicity [14,15]. EspF, a LEE-encoded effector protein, translocates into
host cells in a T3SS-dependent manner. Several previous reports have demonstrated that
EspF disrupts tight junctions, which is followed by a series of events including increasing
mitochondrial membrane permeabilization and cell death, inhibition of bacterial uptake
by macrophages, and restriction of translocation across antigen-sampling M cells in the
gut [16–18]. Furthermore, EspF is involved in the disruption of tight junctions and increases
monolayer permeability through the redistribution of the intermediate filament protein
CK18, rearranging the actin cytoskeleton, and interacting with Arp2/3, ZO-1, ZO-2 and oc-
cludins [16,19–21]. Importantly, several previous reports have shown that EspF sequences
differ among EPEC and EHEC strains. Furthermore, the EspF sequence of the EHEC
O157 variant has a significant impact on transepithelial electrical resistance (TER) [20]. In
addition, EspF, in combination with other effectors, plays a major role in colonization of
E. coli through the inhibition of the water transporter SGLT-1 [22]. EspFEPECO127 targeted
the mitochondria, with the N-terminal region of EspF functioning as an import signal
that accelerates targeting through the mitochondrial membrane protein Tom20 [23,24].
Furthermore, EspFEPECO127 induces mitochondrial membrane permeabilization that is
associated with increased release of cytochrome C from mitochondria into the cytoplasm
and subsequent caspase-9 and caspase-3 cleavage, which, in turn, targets the mitochon-
drial apoptosis pathway and cell death [16,19,24]. EspF interacts with Abcf2 and inhibits
its anti-apoptotic effect, promoting cell apoptosis [19]. A previous study reported that
EspF, in the later stage of infection, targets the nucleolus and leads to the loss of nucle-
olin from the nucleolus into the cytoplasm and a reduction in the level of the ribosomal
protein RPL9 [25]. Moreover, EspFEPECO127 inhibited the phosphatidyl inositol-3 (PI3)
kinase-dependent pathway of bacterial uptake, which represents an important role in E.
coli pathogenesis [26]. A recent study demonstrated that EHEC O157:H7 EspF interacts
with Annexin A6 (Anxa6), which is involved in many biological processes including cell
proliferation, survival, differentiation, and inflammation, which may therefore play an
important role in enhanced O157 persistence [27]. EspF has been shown to function as
hijack host endosomes at bacterial adherence sites. This is considered as an additional
adaptation to facilitate endocytosis and recycling of plasma membrane proteins at these
sites early upon infection. This results in uptake of iron by bacteria that is considered a
critical element for bacterial growth and virulence [28]. EspF was shown to be essential for
infection in vivo using the mouse pathogen Citrobacter rodentium (encoding 31 effectors).
Sequential gene deletions showed that EspF and Map effectors are essential for infection by
maintaining pathogenicity and inducing IL22 secretion and protective immunity to prevent
secondary infection [29]. EspF may mediate DNA damage by regulating the subcellular
localization and phosphorylation of SMC1 [30]. MAD2L2 is necessary for cellular mitosis,
cell cycle checkpoint, DNA damage response (DDR) and most commonly associated with
normal physiological processes [31–36]. The process by DDR components results in a
unique strategy to control cancers [33–36]. EspF is a multifunctional protein that interacts
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with several host cell signaling proteins. For example, EspFEPECO127 can bind to Sorting
Nexin 9 (SNX9) and neuronal Wiskott–Aldrich syndrome protein (N-WASP) via its SH3
amino terminal region that plays a critical role in endocytosis and phagocytosis [37]. This
binding between EspF and N-WASP induces actin polymerization and maturation of the
actin-rich pedestals, promoting the colonization of pathogenic E. coli [21,38,39].
SNX9 is one of these recognized host proteins that, along with N-WASP, plays a
vital role in endocytosis and phagocytosis. In previous work, we used LUMIER binding
assays and demonstrated differences in the interactions of EspF variants with SNX9 and
N-WASP [18]. The results of the LUMIER assays showed that both the EPEC O127 and
EHEC O26 EspF variants had a greater capacity to interact with SNX9 and N-WASP than
the EspF O157 variant. The result may explain the lower ability of the EspF O157 variant to
prevent phagocytosis and inhibit E. coli translocation via a human-derived in vitro M-cell
co-culture system in comparison to EspFO127 and EspFO26. However, it is clear that EspF
has been shown to interact with a myriad of host proteins, and there are potentially other
host proteins involved that have not been identified to date. The work presented here
aimed to identify additional host proteins that interact with the effector protein EspF from
EHEC and EPEC. This information would deepen our understanding of the mechanisms
involved in the different responses to E. coli types in host cells that might trigger therapeutic
targets to intervene and limit E. coli pathogenicity.
2. Materials and Methods
2.1. Gateway Cloning for Screening EspF Protein–Protein Interactions
This step aimed to simplify construction of vectors for Y2H analysis of EspF inter-
actions with eukaryotic proteins. espF alleles were amplified using proofreading, using
an expand long-template PCR system (Roche Diagnostics), using a set of primers, which
are shown in Table 1, then cloned into the Gateway™ vector pDONR-207 (Table 2) using
BP Clonase (Invitrogen, California, USA) to form entry clones. Clones were checked for
the presence of the correct insert by DNA plasmid extraction and restriction digests using
BanII. Once in the Gateway™ system, clones were transferred to the destination vectors
including pTREX-DEST30 (protein A fusions) and pRenilla (luciferase fusions).
Table 1. List of primers used in this study.
Primer Name Sequence Primer Use
1. O26 espF gat fore







3. espFO157 and espFO127gat fore







The recombination reactions (BP reactions) were performed as described elsewhere
with slight modification [18]. Reactions were incubated overnight at room temperature.
One microliter of each reaction was transformed into DH5α competent cells, which were
allowed to recover in SOC medium for 1–2 h at 37 ◦C, then plated on LB plates containing
15 µg/mL gentamycin and incubated overnight at 37 ◦C. The obtained clones were then
checked for the expected insert by plasmid extraction and digestion using BanII.
Gateway Cloning of Different espF Alleles into the pDONR 207 Vector
espF alleles were amplified using primers 1 and 2 for EHEC O26:H11 espF and primers
3 and 4 for EPEC and EHEC O157:H7 espF (Table 1). The PCR products were purified and
then cloned into a donor vector according to the manufacturer’s instructions to form entry
clones. Cloning into the pDONR 207 vector was initially confirmed by restriction digestion
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with BanII (Figure 1). MAD2L2 and Nuclear Factor I C (NFIC) were initially cloned into
the pDONR 223 vector and confirmed by digesting the vector with XbaI and NheI enzymes
and sequencing.
Table 2. List of plasmids used in this study.
Plasmids Description Source
pTREX-DEST30-prA vector to generate amino terminus protein A fusionsfor LUMIER binding assays laboratory stocks
pRenilla Vector to generate amino terminus luciferase fusionsfor LUMIER binding assays laboratory stocks
pAT6-7 espFO157, espFO26 and espFO127 cloned intopTREX-DEST30-prA, respectively this study
pAT8-10 espFO157, espFO26 and espFO127 cloned intopRenilla, respectively this study
pAT11-13 espFO157, espFO26 and espFO127 cloned intopeGFP-DEST, respectively this study
pHJ3 MAD2L2 in pDONR223 Gift from Prof. Juergen Haas,University of Edinburgh, UK
pAT18-20
pTREX-DEST30-MAD2L2, pRenilla-MAD2L2vectors expressing
N-MAD2L2-protein A or -luciferase fusion proteins and MAD2L2
in DSred fusion plasmid pDSRED2-DEST
this study
pHJ4 NFICin pDONR2234 Gift from Prof. Juergen Haas,University of Edinburgh, UK
pAT21-23
pTREX-DEST30-NFIC, pRenilla-NFICvectors expressing
NFIC-protein A or -luciferase fusion proteins and MAD2L2 in
DSred fusion plasmid pDSRED2-DEST
this study
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Figure 1. Comparative analysis of binding between EspF variants and human MAD2L2. In the 
LUMIER binding assay, the espF alleles were expressed with a protein A tag and then immobilized 
on immunoglobulin beads, while MAD2L2 was expressed with Renilla and incubated with the 
immobilized EspF variants (EspFO157, EspFO26, and EspFO127). Inverse combinations were also 
tested. Luminescence signals were then measured and z-scores calculated by subtracting the 
population mean from the individual raw score and then dividing the difference by the population 
Figure 1. Comparative analysis of binding between EspF variants and human MAD2L2. In the
LUMIER binding assay, the espF alleles were expressed with a protein A tag and then immobilized on
immunoglobulin beads, while MAD2L2 was expressed with Renilla and incubated with the immobi-
lized EspF variants (EspFO157, EspFO26, and EspFO127). Inverse combinations were also tested.
Luminescence signals were then measured and z-scores calculated by s btracting the population
mean from th i dividual raw score and then divi ing the differenc by th population standard
deviation, FOS Jun was used as a control positive. MAD2L2 was confirmed to interact with all
EspF variants (EspFO157, EspFO26, and EspFO127). The EspF O26 variant demonstrated the lowest
interaction score of the three EspF binding to MAD2L2.
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2.2. Creation of Expression Clone via LR Reactions
Expression clones can be created by excision, integration, and recombination of entry
clone containing the PCR products by taking advantage of recombination sites using
the LR clonase complex. Destination vectors contain the ccdB gene between the left and
right recombination sites. The LR reaction was carried out using the destination vector
(300 µg/µL), entry clone (150 ng/µL), dH2O and LR clonase enzyme mix (Int, IHF, and
Xis). Reactions were incubated for 3–4 h at room temperature, and 2 µL of each reaction
product were transformed into DH5α chemical competent cells, which were allowed to
recover on SOC medium for 1–2 h at 37 ◦C and then plated on LB plates containing the
appropriate antibiotic and incubated overnight at 37 ◦C. The resulting clones were then
checked for the expected insert by plasmid extraction and restriction digests (EcoRI and
BamHI for Bait and eGFP and XbaI and HindIII for His and Gst fusion construct plasmids).
2.2.1. Sub-Cloning of espF from Entry Clones into Multiple Destination Vectors
espF expression clone was easily transferred into an attP pDONR vector (via the BP
reaction) to generate an entry clone and then into different destination vectors, all without
the need for restriction enzymes and ligase.
2.2.2. Plasmids for Y2H and Colonization
espF entry clones were sub-cloned into the Y2H bait vector pGBKT7-DEST and the eu-
karyotic entry clone library sub-cloned into the prey vector pGADT7-DEST. Both vectors are
destination vectors, with pGADT7-DEST encoding ampicillin resistance and pGBKT7-DEST
encoding kanamycin resistance. The prey and bait clones were confirmed by restriction
digests with EcoRI and BamHI (Figure S1).
2.2.3. Plasmids for LUMIER Pull-Down Assays
A subset of EspF variants and the eukaryotic interaction partner MAD2L2 were
sub-cloned from pDONR207 or pDONR223 into the LUMIER vectors pcDNA-Renilla
and pT-REx-A to validate interactions (Figures S1 and S2, respectively). Both vectors
are expression vectors that also confer ampicillin resistance. The Renilla-tagged clone
sequences were confirmed by digesting with XhoI and XbaI, and the protein A-tagged
clones were confirmed by restriction digests using XhoI and NheI (Figures S1 and S2).
2.2.4. Plasmids for Transient Eukaryotic Expression and Validation of
Y2H-Positive Interaction
In order to examine the possible co-localization of EspF with eukaryotic protein
MAD2L2 in vitro, espF entry clones were sub-cloned into peGFP-DEST vectors containing
N-terminal GFP tags and kanamycin-resistant cassettes. Expression clones were confirmed
by restriction digests using EcoRI and BamHI. MAD2L2 and entry clones were sub-cloned
into pDSRED2-DEST containing an N-terminal PD tag and kanamycin-resistant cassettes
and confirmed by restriction digests with XhoI and NheI (Figure 2).
2.3. Y2H System for Detecting Protein–Protein Interactions
The Y2H system was first described by Fields and Song in 1989 [40], and is currently
used to detect protein–protein interactions in eukaryotic cells. Y2H assays involve a tran-
scription factor consisting of a DNA-binding domain (DNA-BD) that binds to a promoter
and an activation domain that recruits the transcription complex. These domains are not
functional on their own; however, when they are brought together, the activity of the
transcription factor could be restored [40].




Figure 2. Confocal microscopy to validate the interaction of EspF and MAD2L2. Caco-2 cells were transfected with the 
expression plasmid peGFP-DEST (Promega)-expressing EspF tagged with GFP (green) and pDSRED2-DEST (Promega)-
expressing DSred-tagged MAD2L2 (red), the co-localizations indicated by yellow color. After 48 h, cells were fixed and 
permeabilized with 2% (w/v) formalin/0.25% (v/v) Triton X-100. The cells were then incubated with DAPI to stain the 
nucleus (blue). Slides were mounted in fluorescence mounting medium (DAKO) and images acquired using a Leica TCS 
NT confocal system with a 63× objective. Scale bar 10 μm. 
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Figure 2. Confocal microscopy to validate the interaction of EspF and MAD2L2. Caco-2 cells were transfected with the
expression plasmid peGFP-DEST (Promega)-expressing EspF tagged with GFP (green) and pDSRED2-DEST (Promega)-
expressing DSred-tagged MAD2L2 (red), the co-localizations indicated by yellow color. After 48 h, cells were fixed and
permeabilized with 2% (w/v) formalin/0.25% (v/v) Triton X-100. The cells were then incubated with DAPI to stain the
nucleus (blue). Slides were mounted in fluorescence mounting medium (DAKO) and images acquired using a Leica TCS
NT confocal system with a 63× objective. Scale bar 10 µm.
2.4. Direct Mating for Y2H Screens
Yeast bait and prey clones were streaked out from glycerol stocks on selective agar
plates and incubated for 1–3 days at 30 ◦C. Haploid yeast cells were inoculated in 5 mL
liquid medium for pre-cultures and then 5 mL of freshly grown yeast inoculated in 25 mL
of singly selective liquid medium, either SD-Trp for bait or SD-Leu for prey. Cultures
were incubated overnight at 30 ◦C and 220 rpm in an appropriate vessel that prevented
cells from growing at high densities. Next, 100 µL of mating media (SD-Leu-Trp with 5%
YPDA) were added to the required number of wells of a U-bottom microtiter plate, with a
U-bottom plate used to ensure close proximity of yeast cells. Bait and prey cultures were
resuspended in mating media to an OD600 of 1.0–1.2 and 25 µL of resuspended culture and
transferred to each appropriate well of the mating plate. The plate was then centrifuged at
2000 rpm for 30 s at room temperature to bring cells in close proximity to each other at the
bottom of each well to facilitate mating. The plate(s) were incubated at 30 ◦C overnight.
The wells of a flat-bottom microtiter plate were filled with 150 µL of fresh double-selective
media (SD-Leu-Trp containing penicillin/streptomycin) for diploid selection. Yeast pellets
in the mating plate were resuspended and 10 µL transferred from each culture to the
diploid selection plate and incubated at 30 ◦C without shaking for 2 days. Diploid cells
were then checked visually for growth until saturation or near saturation were reached.
Triple-knockout SD media (with no Trp, Leu, or His) containing the fluorescent detection
compound 4-MuX and the bait auto-activation inhibitor 3-AT was then prepared. Duplicate
assay plates were prepared by adding 150 µL of detection media (detection plate) or SD-LW
(control diploid selection plate) to a sufficient number of wells of flat-bottom microtiter
plates. iploid cultures were suspended in the diploid selection plate and 10 µL of each
culture transferred to the detection and control plate, covered with gas-permeable lids,
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and placed in plastic bags, then incubated at 30 ◦C for 3–7 days, with no shaking. Cells
were suspended in the control plate and absorbance measured at OD600 relative to media-
only negative controls to confirm yeast cell growth and mating success. The fluorescence
readout was measured using a fluorescence reader, with excitation at 365 nm and emission
at 448 nm.
2.5. LUMIER Assays
For the LUMIER assays, proteins were either fused with Staphylococcus aureus protein
A or Renilla reniformis luciferase was fused at their amino termini before being transiently
expressed in Caco-2 cells. Each expression construct (20 ng) was transfected into Caco-2
cells using 0.05 µL of lipofectamine 2000 (Invitrogen) in 96-well plates. After 40 h, the
media were removed, and the cells were lysed on ice in 10 µL of ice-cold lysis buffer (20 mM
Tris pH 7.5, 250 mM NaCl, 1% Triton X-100, 10 mM EDTA, 10 mM DTT, Protease Inhibitor
Cocktail (Roche), Phosphatase Inhibitor Cocktail (Roche), and 25 units/µL Benzonase
(Novagen)). Sheep-anti-rabbit IgG-coated magnetic beads were then added (Invitrogen,
Dynabeads M280, 2 mg/mL final concentration) and the mixture was incubated on ice
for 15 min. Next, 100 µL of washing buffer (PBS, 1 mM DTT) were added to each well
and 10% of the diluted lysate removed to determine the luciferase activity present in each
sample before washing. The rest of the sample was washed 6 times in washing buffer,
and luciferase activity was measured in both lysate-washed beads. Negative controls
consisted of wells transfected with plasmids expressing a luciferase fusion protein and
protein A dimers were included. Negative controls were wells transfected with the plasmid
expressing the luciferase fusion protein and a vector expressing a dimer of protein A.
Normalised interaction signals were z-transformed by subtracting the mean and dividing
by the standard deviation. The mean and standard deviation were calculated from large
datasets of protein pairs which were expected to interact, i.e., from negative reference sets.
2.6. Transfection of Adherent Caco-2 Cells Using Effectene
The enhancer was used first to condense DNA; then, the Effectene reagent (Qiagen,
UK) was used to coat the condensed DNA molecules with cationic lipids. Cells were plated
in wells of 48-well plates at a density of 5 × 104 cells/well in 400 µL DMEM with 10%
(v/v) fetal calf serum (FCS, Sigma, Dorset, United Kingdom), 1 U of penicillin (Invitrogen,
Paisley, United Kingdom), 1 µg/ml of streptomycin (Invitrogen, Paisley, United Kingdom)
and 2 mM of L-glutamine (Invitrogen, Paisley, United Kingdom) 48 h before transfection
in order to reach optimal transfection conditions of 40–70% confluence (approximately
2 × 105 cells/well). Total DNA (150 ng) was then diluted in EC buffer to a final volume of
50 and 1.2 µL of enhancer, after which the solution was mixed by vortexing and incubated
for 5 min at room temperature to allow for formation of condensed DNA. Next, 4 µL of
Effectene transfection reagent were added to the aforementioned solution and incubated for
10 min at room temperature for DNA transfection complex formation. Cell media were then
removed from each plate, cells washed with PBS, and 200 µL of fresh DMEM containing
serum and antibiotics added to each well. After lipid–DNA complex formation, 200 µL of
fresh DMEM containing serum and antibiotics were then added to the DNA mixture, which
was then placed onto adherent cells drop by drop and swirled to ensure an even distribution.
Protein expression levels were determined 48–72 h post-transfection. The transfection
efficiency was determined after 24 h using eGFP expression as a positive readout.
2.7. Confocal Microscopy
Caco-2 cells grown on chamber glass slides were transfected with N-terminally GFP-
tagged EspF expressed from pAT11-13 and DSred-tagged MAD2L2 expressed from pAT20
(Table 2). The cells were either fixed in 2% (v/v) Formalin or fixed/permeabilized in 2%
(v/v) Formalin-0.2% (v/v) Triton X-100 for 20 min at room temperature. Cells were then
treated for 20 min at room temperature with 1/5000 DAPI (Molecular Probes), washed
twice with PBS and mounted in fluorescent mounting medium (DAKO). The confocal
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data were acquired using a Zeiss Plan Apochromat 1.4 NA with a 63× oil immersion lens
and a multi-track (sequential scan) experimental setup on a Zeiss LSM510 with images
taken at a pixel image size of 1024 × 1024. Image data were acquired at Nyquist sampling
rates and deconvolved using Huygens software (Scientific Volume Imaging, Laapersveld
63, 1213 VB Hilversum, The Netherlands). The resulting three-dimensional models were
analyzed, and orthogonal views were created using NIH ImageJ software, with final figures
assembled using Adobe Photoshop. The colocalization of the percentage of MAD2L2 and
EspF variants was performed using ImageJ software.
3. Results
3.1. MAD2L2 Is a Novel EspF Interacting Partner
In previous work, we have confirmed that EspF interacts with SNX9 and N-WASP,
confirming its critical role during infection [18]. Furthermore, we have shown differences
between EPEC and EHEC resistance to phagocytosis that was attributed to the interaction
of their EspF variants with SNX9 and N-WASP using LUMIER binding assays [18]. In order
to identify more cellular ligands that might interact with this type 3 effector protein, EspF
variants were screened against a human cDNA library using the Y2H system [41]. The
mating between the bait strain, containing EspF variants, and the prey strain, containing
cDNA for a human protein library, suggested a new protein hit for EspF, with an interaction
between EspF from EHEC O26:H11 and the host MAD2L2 protein. In stark contrast, no
interaction was detected between EspF and EPEC O127:H6.
3.2. Binding Activity of the Three EspF Variants to MAD2L2
In order to verify the results of the Y2H screen, and to investigate the differential
quantitative levels of the binding activity of the three EspF variants to human MAD2L2
protein, LUMIER binding assays were carried out. MAD2L2 and EspF variants (EspFO157,
EspFO26, and EspFO127) were cloned into plasmids that expressed either protein A-tagged
proteins or Renilla luciferase fusion proteins and vice versa. These plasmids were then
transiently expressed in Caco-2 cells. Negative controls consisted of wells transfected with
plasmids expressing a luciferase fusion protein and protein A dimers were also used [42].
Cell lysates containing both sets of tagged proteins were generated and then the protein
A-tagged complexes were removed using antibody-coated beads. The total fluorescence
and captured fluorescence were measured and z-scores for each interaction calculated
by comparison with a large bank of negative non-interacting controls. Interestingly, we
found that all EspF variants (EspFO157, EspFO26, and EspFO127) interacted with MAD2L2
and these quantitative results demonstrated that EspFO26 had the lowest binding affinity
to MAD2L2 of the three investigated variants, but this difference was not statistically
significant (Figure 1). The interaction between EspF variants with MAD2L2 suggests that
all three bacterial EspF have the ability to bind and activate MAD2L2.
3.3. Demonstration of the Intracellular Interaction of EspF and MAD2L2
Caco-2 epithelial cells were double-transfected with N-terminally GFP-tagged EspF
expressed from pAT11-13 and DSred-tagged MAD2L2 expressed from pAT20 to confirm
that different EspF variants are able to bind to MAD2L2 and examine the relative intra-
cellular distribution of these protein complexes. Confocal microscopy examination of the
transfected cells revealed that, at 48 h, all the generated EspF protein, irrespective of EspF
variant, co-localized with MAD2L2 in the cell nuclei, which did not yet show any sign
of cell apoptosis (Figure 2). Extending the incubation time to 72 h before fixation still
found a distinct co-localization of EspF variants with MAD2L2 inside the nucleus of each
transfected cell. However, cellular vacuolation was observed, suggesting that apoptotic
cell death had been induced (Figure 3). We determined the percentage of co-localization
by dividing the area of co-localization by the total fluorescence of the whole cell. We also
found that the percentage of co-localization of the EspF variants, EspFO157, EspFO26, and
EspFO127, with MAD2L2 was 21.76% ± 2.2, 19.85% ± 0.65, and 28.87% ± 2.73, respectively,
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and there was no significant difference between each other using ANOVA. These results
correlate with the quantitative LUMIER binding studies (Figure1) and further confirm the
interaction between EspF variants and MAD2L2 protein inside the nuclei. In addition, the
present results suggest a mechanism behind how EspF increases the ability of different
pathogenic E. coli to reinforce their colonization inside epithelial cells through inactivation
of MAD2L2 protein, which, in turn, leads to activation of the anaphase-promoting complex
APC/cyclosome, thus inhibiting epithelial cell turnover and reducing E. coli removal from
the site of infection.
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t t since they are a major cause of human diseases [ 3,44]. Diarrhoea in infants
and young children is mainly caused by EPEC [45], while EHEC infection leads t mor-
tality orldwide through acute renal failure and hemolytic uremic syndrome [43]. It is
te rt t state t at t a ersist i a r a i al sts t r
attach ent to epithelial cells that line the gastrointestinal tract [4]. These pathogenic
bacteria use Type III secreted effector proteins to manipulate the actin cytoskeleton and
innate responses of host cells to enable intimate bacterial attachment and persistence [46].
T3SS-induced translocation of the effector protein EspF results in tight junction disruption,
water channel dysregulation and inhibition of bacterial uptake into M cells [17,39]. The
EspF effector protein has been demonstrated to localize in both the host cell mitochondria
and nuclei [16,18,25] and is known to interact with SNX9, N-WASP, and ABCF2 [19,38].
This current study presents interesting data concerning the molecular mechanism by which
pathogenic E. coli may promote their colonization of intestinal epithelial cells, support-
ing the role of EspF interacting with the cell cycle protein MAD2L2. To elucidate this
protein–protein interaction, we implemented a Y2H screening system, which is considered
an excellent evolving system for high-throughput screening of protein–protein interac-
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tions [41]. In previous work, we established that there are differences between the ability of
EPEC and EHEC strains to resist phagocytosis by macrophages and transcytosis by M-like
cells, which we attributed to variation in the interaction of their different EspF proteins
with SNX9 and N-WASP using LUMIER binding assays [18].
In the present study, the Y2H system was used to screen EspF bait clones against a
human cDNA library prey, which resulted in a successful mating between bait strain con-
taining EspF and the prey strain containing cDNA library protein, identified as MAD2L2,
and the reconstitution of transcription factor activity that further indicated a protein–
protein interaction. This bait-prey interaction-induced transcription factor activity led to
the expression of the easily detectable reporter gene producing the characteristic fluores-
cence. Previously, the molecular mechanisms by which E. coli T3SS-effector protein EspF
induced apoptosis in the intestinal epithelial barrier of the host were shown to be indis-
tinct [47]. The results of this current study have begun to answer this important question.
Using LUMIER assays, we confirmed the ability of EspF variants from EHEC O157:H7
and O26:H11, as well as EPEC O127:H6, to interact with the anaphase-promoting complex
(APC) inhibitor; MAD2L2. Taken together, these studies suggest a novel mechanism by
which EspF can slow epithelial cell turnover and confer an advantage for prolonged bac-
terial colonization [48]. It is noteworthy to state that confocal microscopy has been used
to confirm co-localization of EspF and MAD2L2 inside the nuclei of epithelial cells. The
binding of EspF variants with MAD2L2 after 48 h inside the nuclei of Caco-2 cells is in
agreement with a similar recent finding in HEK293 cells [49], again without inducing cell
apoptosis (Figure 2). However, by 72 h, cells co-expressing EspF and MAD2L2 showed the
characteristics of apoptosis (Figure 3), suggesting that this protein–protein interaction is
inhibiting the cell cycle [50]. This novel identification of MAD2L2 as a target of the EHEC
and EPEC effector protein EspF is in line with a previous report that MAD2L2 is targeted
by the non-homologous Shigella effector protein IpaB to limit epithelial cell turnover [48].
This interaction of EspF with the cell cycle key player MAD2L2 would be expected to
greatly affect the cell cycle and confer an advantage for bacterial survival.
The MAD2-related protein MAD2L2 is an inhibitor of the APC Cdh1 [51–53]. Activa-
tion of the APC during interphase (G1/S) leads to cell cycle arrest at G2/M. The interaction
between Cdh1 and MAD2L2 has been shown to result in the inhibition of Cdh1-APC
complex activity; thus, MAD2L2 may play an important role as a mitotic spindle assem-
bly checkpoint protein [53], preventing the onset of anaphase until all chromosomes are
properly aligned at the metaphase plate. MAD2L2 also plays a pivotal role in translational
DNA synthesis in the S phase [54] and, similar to MAD2L2, participates in the spindle
assembly checkpoint [55]. MAD2L2 has been shown to bind to the TCF4-catenin forming
interaction complex that inhibits differentiation to Epithelial mesenchymal transition (EMT)
and enhances proliferation of epithelium cells [56,57]. Shigella IpaB was shown to sequester
MAD2L2 away from the APC-Cdh1 complex, leading to unregulated APC activity during
interphase and subsequent cell cycle arrest [48]. Cell division plays an essential role in
innate immunity, as the rapid turnover of epithelial cells limits bacterial colonization.
Therefore, slowing this turnover could increase the ability of bacteria to multiply and hence
prolong bacterial colonization [48]. Clearly, the present results add new knowledge to our
understanding of the molecular pathogenesis of EHEC and EPEC and their weapons to
ensure efficient colonization inside the host epithelial cells. Based on this new detailed
understanding, abolishing the EspF interaction with MAD2L2 could be a therapeutic target
to limit bacterial colonization, pathogenicity and severity of the diseases caused by EHEC
and EPEC.
5. Conclusions
The present study revealed the ability of EHEC and EPEC effector protein EspF to
interact with and bind to MAD2L2. MAD2L2 normally inhibits the anaphase-promoting
complex APC/cyclosome. The binding of EspF to MAD2L2 will free the APC, which
stops the cell cycle progression and prevents epithelial cell turnover. As cellular turnover
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is a key method for bacteria removal from the epithelium, stopping MAD2L2 activity
promotes bacterial colonization in the intestinal mucosa. Collectively, the present results
added more depth to the understanding of EHEC and EPEC molecular pathogenesis and
abolishing this reported interaction in future studies could be helpful in designing novel
therapeutic targets for combating the diseases caused by EHEC and EPEC. Further future
research is also warranted to address whether the translocated EspF into the cells following
infection interacts with MAD2L2 and its co-localization, combined with exploring the
possible involvement of this interaction on cell cycle and/or APC/C parameters.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/life11090971/s1, Figure S1: Gateway cloning of different espF alleles to study protein–protein
interactions. Scanned image of gel red-stained 1% TAE agarose gel shows PCR amplification of the
espF alleles from EPEC O127:H6 and the EHEC serotypes O157:H7 and O26:H11 (A). BanII digests of
different espF clones in the entry vector pDONR207 (B) and EcoRI and BamHI digests of different ORF
clones in bait constructs (C). EcoRI and BamHI digests of different espF clones in the peGFP vector (C).
XhoI and XbaI digests of different ORF clones in the pcDNARenilla vector (D). XhoI and NheI digests
of different ORF clones in pTREX (D). Lane M contains the 1 kbp-plus DNA ladder (Invitrogen),
and lanes 1–3 espF show results for EPEC O127:H6 and EHEC serotypes O157:H7 and O26:H11,
respectively; Figure S2. Gateway cloning of Mad2L2 gene for protein–protein interaction studies.
Scanned image of gel red-stained 1% TAE agarose gels showing results of XhoI and XbaI digests
of mad2L2 clone in the entry vector pDONR223 (A), which were then cloned into two different
destination vectors to create expression clones. EcoRI and BamHI digests of different ORF clones of
bait (B) and prey (C) constructs. XhoI and XbaI digests of different ORF clones in the pcDNARenilla
vector (D). XhoI and NheI digests of different ORF clones in pTREX (E). EcoRI and BamHI digests of
different ORF clone into PDSred (F). Lane M contains the 1 kbp plus DNA ladder.
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